Kiniksa Pharmaceuticals International (KNSA) Competitors $27.44 +0.20 (+0.73%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$27.21 -0.23 (-0.84%) As of 07/2/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. BPMC, VRNA, BBIO, ROIV, RVMD, ELAN, LEGN, GRFS, TLX, and TGTXShould you be buying Kiniksa Pharmaceuticals International stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals International include Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals International vs. Its Competitors Blueprint Medicines Verona Pharma PLC American Depositary Share BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health Legend Biotech Grifols Telix Pharmaceuticals TG Therapeutics Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Is KNSA or BPMC more profitable? Kiniksa Pharmaceuticals International has a net margin of -3.52% compared to Blueprint Medicines' net margin of -27.70%. Kiniksa Pharmaceuticals International's return on equity of -3.83% beat Blueprint Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Kiniksa Pharmaceuticals International-3.52% -3.83% -2.98% Blueprint Medicines -27.70%-64.60%-17.22% Which has more risk and volatility, KNSA or BPMC? Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Do insiders & institutionals believe in KNSA or BPMC? 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has better valuation & earnings, KNSA or BPMC? Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Blueprint Medicines. Kiniksa Pharmaceuticals International is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiniksa Pharmaceuticals International$423.24M4.73-$43.19M-$0.25-109.76Blueprint Medicines$508.82M16.27-$67.09M-$2.47-51.90 Do analysts prefer KNSA or BPMC? Kiniksa Pharmaceuticals International presently has a consensus price target of $38.80, indicating a potential upside of 41.40%. Blueprint Medicines has a consensus price target of $128.06, indicating a potential downside of 0.11%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, research analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiniksa Pharmaceuticals International 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.27 Does the media refer more to KNSA or BPMC? In the previous week, Blueprint Medicines had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 8 mentions for Blueprint Medicines and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Blueprint Medicines' score of 0.96 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiniksa Pharmaceuticals International 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKiniksa Pharmaceuticals International beats Blueprint Medicines on 11 of the 17 factors compared between the two stocks. Get Kiniksa Pharmaceuticals International News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa Pharmaceuticals InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-109.7621.3126.1719.90Price / Sales4.73278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book4.167.518.025.38Net Income-$43.19M-$55.05M$3.15B$248.50M7 Day Performance-3.69%2.07%1.48%2.06%1 Month Performance-5.74%4.84%3.66%4.86%1 Year Performance43.66%5.37%34.68%20.24% Kiniksa Pharmaceuticals International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals International3.7148 of 5 stars$27.44+0.7%$38.80+41.4%+48.7%$1.99B$423.24M-109.76220BPMCBlueprint Medicines1.5574 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.28B$508.82M-51.98640High Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.5901 of 5 stars$97.05+2.9%$101.10+4.2%+482.7%$8.03B$42.28M-48.5330Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.7128 of 5 stars$42.17+1.1%$56.67+34.4%+71.9%$7.92B$221.90M-11.95400Analyst ForecastInsider TradeROIVRoivant Sciences1.9443 of 5 stars$11.50+0.4%$17.50+52.2%+3.9%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.4993 of 5 stars$40.04+1.0%$67.08+67.5%-0.5%$7.39B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.3429 of 5 stars$13.36-0.7%$15.17+13.5%+5.1%$6.68B$4.44B18.059,000Analyst ForecastLEGNLegend Biotech3.4951 of 5 stars$33.85-0.4%$76.20+125.1%-19.7%$6.25B$627.24M-57.372,609News CoveragePositive NewsAnalyst ForecastGRFSGrifols4.137 of 5 stars$8.37-4.6%$10.30+23.1%+40.2%$6.03B$7.81B7.1523,822TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.80B$516.72M0.00N/AGap DownHigh Trading VolumeTGTXTG Therapeutics3.7706 of 5 stars$36.56+1.5%$40.80+11.6%+98.2%$5.72B$329M152.33290 Related Companies and Tools Related Companies Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Grifols Alternatives Telix Pharmaceuticals Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals International, plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
